Psychiatric safety concerns lead to Acomplia suspension
This article was originally published in Scrip
The European Medicines Agency has recommended that Sanofi-Aventis's obesity treatment Acomplia (rimonabant) be temporarily suspended across the EU owing to concerns over psychiatric safety, and the company says it will comply with the recommendation.
You may also be interested in...
Pharmaceutical industry groups say the European Commission’s Pharmaceutical Strategy Roadmap lacks detail on delivering a faster regulatory process and encouraging competitiveness.
The Australian Therapeutic Goods Administration is consulting on a draft standard for data matrix codes on the labels of certain medicines.
The European Medicines Agency received more requests for scientific advice in 2019 than it did in 2018. Meanwhile, requests for advice in other areas has fallen.